2017.Jun.11

Supplemental information on the approved application of Phase III clinical trial of OBI-822, the novel breast cancer drug, in China, US, and the EU

Date of occurrence: June 11, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding ratios: N/A Name of mass media: CNA News E-Paper Content reported: During the preparation court hearing on OBI’s insider trading case on June 9, Michael Chang emphasized that OBI’s novel […]

HOMEWhat’s NewAnnouncementsSupplemental information on the approved application of Phase III clinical trial of OBI-822, the novel breast cancer drug, in China, US, and the EU

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2017.Jun.01

OBI Pharma Announces Acquisition of the Novel First-in-class Anti-Cancer Drug OBI-3424 from Threshold Pharmaceuticals to be Developed as Potential Anti-Cancer Therapy for Cancers with High AKR1C3

2017.Jun.28

Important Resolutions of AGM 2017